Product Information

CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Micro Labs Limited, priced at $0.2760 per EA under NDC 42571038101. Its NADAC has been published 166 times since Sep 13, 2023.

FDA first approved this application on Jul 19, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CHLORDIAZEPOXIDE-CLIDINIUM CAP

CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE
$0.2760per EA
DEA Schedule CIV

Strength

5; 2.5 mg/1; mg/1

Manufacturer

Micro Labs Limited

NDC

42571038101

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA215835

FDA Approved

7/19/2022

TE Code

AB

On Market Since

10/1/2022

Pharmacological Classes

Anticholinergic
Benzodiazepine
Benzodiazepines
Cholinergic Antagonists
Decreased Parasympathetic Acetylcholine Activity
Digestive/GI System Activity Alteration
GI Motility Alteration

Price Statistics

The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 166 times since Sep 13, 2023, and over the history we have for it it has risen 5.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2760 per EA
All-time high$0.5272 (Oct 16, 2024)
All-time low$0.2405 (Mar 18, 2026)
52-week high$0.2760
52-week low$0.2405
Median price$0.2893
Average price$0.3112
Largest weekly change+78.0% (Aug 21, 2024)
Weeks tracked166
Tracking sinceSep 13, 2023

Price History

1W

0.0%

1M

+7.8%

3M

+8.4%

6M

+1.7%

1Y

-6.1%

3Y

-18.9%

5Y

N/A

All

+5.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?

The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Micro Labs Limited, is $0.2760 per EA (NDC 42571038101), effective Nov 11, 2026.

How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?

Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has risen 5.9%. It has been tracked across 166 weekly CMS publications since Sep 13, 2023.

What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?

Since Sep 13, 2023, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2405 (Mar 18, 2026) to a high of $0.5272 (Oct 16, 2024), with a median of $0.2893 per EA.

Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?

No other NADAC-published product currently shares the active ingredient and strength of CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?

CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 42571038101) is labeled by Micro Labs Limited, and CMS classifies it as a generic product.